GLP-1 drugs have revolutionized the treatment of obesity, achieving unprecedented improvements in weight loss and overall health. However, despite its remarkable effectiveness, most patients discontinue treatment within months, regaining their weight and missing out on many of the health benefits they had striven to achieve. Investing in Obesity Medicine explores the pivotal question that has been largely overlooked by healthcare leaders, physicians, investors, and entrepreneurs:If science works, why does the system fail? Drawing on direct clinical experience and years of designing large-scale obesity programs, White reveals the hidden structural barriers that prevent millions of people from achieving lasting treatment success.
Combining a healthcare manifesto, business strategy, and practical blueprint, this book challenges conventional thinking about obesity care and the role of markets in medicine.Through poignant patient stories, careful analysis of the reality of obesity treatment, and lessons from some of the world's most successful consumer companies, readers are introduced to a new model for delivering scalable and sustainable obesity care. Whether you're a healthcare professional, policymaker, entrepreneur, investor, or patient advocate, this unique guide offers inspiring, practical insight for solving one of the most important public health challenges of our time.
